Company: MDCXW
Filing Date: 2025-08-12
Form Type: 424B3
Source: 0001062993-25-014093
Chunk: 32

Company: Medicus Pharma Ltd.
Filing Date: 2025-08-12
Form: 424B3
Chunk 32
---
 market price (as defined in the SEPA) of the common shares during a specified three-day pricing period. The Company reserves the right to set a minimum acceptable price for the common share issuances. Cash flows

|                                       |     | For the six months ended June 30 
                             2025 |   |     |       2024 |   |     |            |   |
|:--------------------------------------|:----|---------------------------------:|:--|:----|-----------:|:--|:----|-----------:|:--|
|                                       |     |                                $ |   |     |          $ |   |     |     Change |   |
| Cash used in operating activities     |     |                       (9,409,825 | ) |     | (3,953,639 | ) |     | (5,456,186 | ) |
| Cash provided by financing activities |     |                       14,915,048 |   |     | 10,642,500 |   |     |  4,272,548 |   |
| Net change in cash during the period  |     |                        5,505,223 |   |     |  6,688,861 |   |     | (1,183,638 | ) |
| Cash, beginning of the period         |     |                        4,164,323 |   |     |  1,719,338 |   |     |  2,444,985 |   |
| Cash, end of the period               |     |                        9,669,546 |   |     |  8,408,199 |   |     |  1,261,347 |   |

Cash flows used in operating activities Cash flows used in operating activities for the six months ended June 30, 2025 were $9,409,825 compared to cash flows used in operating activities of $3,953,639 for the six months ended June 30, 2024. The increase is primarily due to increased spending on research and development activities for our SKNJCT-003 study and trials and increased general and administrative expenses related to our IPO and resulting U.S. reporting obligations, along with multiple financing and other transactional activities. Cash flows provided by financing activities Cash flows provided by financing activities for the six months ended June 30, 2025 were $14,915,048 due to $9,790,015 of proceeds from issuance of common shares and